Managing multidrug-resistant tuberculosis in children: Review of recent developments

Current Opinion in Infectious Diseases

Volumn 27, Issue 3, 2014, Pages 211-219

  Schaaf, H Simon ^a   Garcia Prats, Anthony J ^a   Hesseling, Anneke C ^a   Seddon, James A ^a,b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

children; diagnosis; multidrug resistant tuberculosis; prevention; treatment

Indexed keywords

CLOFAZIMINE DERIVATIVE; ETHYLENEDIAMINE DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; ETHIONAMIDE; MOXIFLOXACIN; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL THERAPY; CASE FINDING; CHILDHOOD DISEASE; CONTACT EXAMINATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; INFECTION PREVENTION; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; CHILD; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION; INFANT; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; ETHIONAMIDE; FLUOROQUINOLONES; HUMANS; INFANT; NITROIMIDAZOLES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PYRAZINAMIDE; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84900500130     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000062     Document Type: Review

References (76)

1. World Health Organization. Global tuberculosis control: WHO report 2010. WHO, Geneva, Switzerland. WHO/HTM/TB/2010.7; 2010.
2. World Health Organization. Global tuberculosis report 2013. WHO, Geneva, Switzerland. WHO/HTM/TB/2013.11; 2013.
3. Zignol M, Sismanidis C, Falzon D, et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013; 42:701-707.
4. Kapata N, Chanda-Kapata P, Bates M, et al. Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011. Trop Med Int Health 2013; 18:1386-1391.
5. Seddon JA, Hesseling AC, Marais BJ, et al. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012; 16:928-933.
6. The Sentinel Project on Pediatric Drug-resistant Tuberculosis. http://sentinel-project.org/. [Accessed 20 January 2014]
7. Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953-964.
8. Seddon JA, Perez-Velez CM, Schaaf HS, et al. Consensus statement on research definitions for drug-resistant tuberculosis in children. J Pediatr Infect Dis Soc 2013; 2:100-109.
9. World Health Organization. Roadmap for childhood tuberculosis: towards zero deaths. WHO, Geneva, Switzerland. WHO/HTM/TB/2013.12; 2013.
10. Shah M, Chihota V, Coetzee G, et al. Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis 2013; 13:352.
11. Barnard M, Gey van Pittius NC, van Helden PD, et al. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012; 50:3712-3716.
12. Garg RK, Jain A, Malhotra HS, et al. Drug-resistant tuberculous meningitis. Expert Rev Anti Infect Ther 2013; 11:605-621.
13. Walters E, Gie RP, Hesseling AC, et al. Rapid diagnosis of pediatric intrathoracic tuberculosis from stool samples using the Xpert MTB/RIF assay: a pilot study. Pediatr Infect Dis J 2012; 31:1316.
14. Nicol MP, Spiers K, Workman L, et al. Xpert MTB/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children. Clin Infect Dis 2013; 57:e18-e21.
15. Hillemann D, Rusch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 2011; 49:1202-1205.
16. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11:819-824.
17. Mukinda FK, Theron D, van der Spuy GD, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 2012; 16:196-202.
18. Dramowski A, Morsheimer MM, Jordaan AM, et al. Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa. Int J Tuberc Lung Dis 2012; 16:76-81.
19. Kurbatova EV, Cavanaugh JS, Shah NS, et al. Rifampicin-resistant Myco-bacterium tuberculosis: susceptibility to isoniazid and other antituberculosis drugs. Int J Tuberc Lung Dis 2012; 16:355-357.
20. Schaaf HS, Seddon JA. Epidemiology and management of childhood multi-drug-resistant tuberculosis. Clin Pract 2012; 9:701-713.
21. Yuen CM, Tolman AW, Cohen T, et al. Isoniazid-resistant tuberculosis in children: a systematic review. Pediatr Infect Dis J 2013; 32:e217-e226.
22. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377:147-152.
23. Grandjean L, Crossa A, Gilman RH, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 2011; 15:1164-1169.
24. Becerra MC, Franke MF, Appleton SC, et al. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J 2013; 32:115-119.
25. Parr JB, Mitnick CD, Atwood SS, et al. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis 2014; 58:392-395.
26. Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in house-holds of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2014; 58:381-391.
27. Singla N, Singla R, Jain G, et al. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis 2011; 15:1326-1330.
28. Johnston J, Admon A, Ibrahim A, et al. Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a low incidence setting. BMC Infect Dis 2012; 12:266.
29. Tochon M, Bosdure E, Salles M, et al. Management of young children in contact with an adult with drug-resistant tuberculosis, France 2004-2008. Int J Tuberc Lung Dis 2011; 15:326-330.
30. Seddon JA, Hesseling AC, Finlayson H, et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013; 57:1676-1684.
31. Tuberculosis Research Centre Indian Council of Medical Research ICI. Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-suscep- tible cases. Int J Tuberc Lung Dis 2011; 15:782-788.
32. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011; 12:31-38.
33. Cruz AT, Starke JR. A current review of infection control for childhood tuberculosis. Tuberculosis (Edinb) 2011; 91 (Suppl 1):S11-S15.
34. Curtis AB, Ridzon R, Vogel R, et al. Extensive transmission of Mycobacterium tuberculosis from a child. N Engl J Med 1999; 341:1491-1495.
35. Cruz AT, Medina D, Whaley EM, et al. Tuberculosis among families of children with suspected tuberculosis and employees at a children's hospital. Infect Control Hosp Epidemiol 2011; 32:188-190.
36. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO, Geneva, Switzerland. WHO/HTM/TB/2008.402; 2008.
37. European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm: ECDC; 2012.
38. van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012; 16:288-296.
39. Seddon JA, Godfrey-Faussett P, Hesseling AC, et al. Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis 2012; 12:469-479.
40. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J 2011; 30:501-505.
41. Poorana Ganga Devi NP, Swaminathan S. Drug-resistant tuberculosis: pediatric guidelines. Curr Infect Dis Rep 2013; 15:356-363.
42. Thee S, Seifart HI, Rosenkranz B, et al. Pharmacokinetics of ethionamide in children. Antimicrob Agents Chemother 2011; 55:4594-4600.
43. Chauny JV, Lorrot M, Prot-Labarthe S, et al. Treatment of tuberculosis with levofloxacin or moxifloxacin: report of six pediatric cases. Pediatr Infect Dis J 2012; 31:1309-1311.
44. Thee S, Garcia-Prats AJ, Draper HR, et al. Pharmacokinetics of ofloxacin and levofloxacin in children with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17:S255.
45. Hesseling AC. Pharmacokinetics of second line TB therapy in children. In 43rd Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 2012. http://uwclh.conference2web.com/content/1894/details?from-view= all&view-address=page%3D10. [Accessed 10 January 2014]
46. Donald PR, Ahmed A, Burman WJ, et al. Requirements for the clinical evaluation of new antituberculosis agents in children. Int J Tuberc Lung Dis 2013; 17:794-799.
47. Seddon JA, Hesseling AC, Marais BJ, et al. Paediatric use of second-line antituberculosis agents: a review. Tuberculosis (Edinb) 2012; 92:9-17.
48. Garazzino S, Scolfaro C, Raffaldi I, et al. Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience. Pediatr Pulmonol 2014; 49:372-376.
49. Furin J, Brigden G, Lessem E, Becerra MC. Novel pediatric delivery systems for second-line antituberculosis medications: a case study [Case study]. Int J Tuberc Lung Dis 2013; 17:1239-1241.
50. Hallbauer UM, Schaaf HS. Ethionamide-induced hypothyroidism in children. S Afr J Epidemiol Infect 2011; 26:161-163.
51. Thee S, Zollner EW, Willemse M, et al. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011; 15:1191-1193.
52. Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect 2013; 66:320-329.
53. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:684-692.
54. Wiseman CA, Gie RP, Starke JR, et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J 2012; 31:347-352.
55. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 2013. [Epub ahead of print]
56. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:449-456.
57. Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012; 16:1588-1593.
58. Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011. Int J Tuberc Lung Dis 2013; 17:624-629.
59. Satti H, McLaughlin MM, Omotayo DB, et al. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One 2012; 7:e37114.
60. World Health Organization. Global tuberculosis report 2012. WHO, Geneva, Switzerland. WHO/HTM/TB/2012.6; 2012.
61. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4:e6914.
62. Kjollerstrom P, Brito MJ, Gouveia C, et al. Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: experience of a paediatric infectious diseases unit. Scand J Infect Dis 2011; 43:556-559.
63. Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb) 2014; 94:93-104.
64. Dey T, Brigden G, Cox H, et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Anti-microb Chemother 2013; 68:284-293.
65. Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014; 4:e004143.
66. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014; 383:1230-1239.
67. Diacon AH, von Groote-Bidlingmaier F, Donald PR. Delamanid, a new 6-nitro-2, 3-dihydroimidazo[2, 1-b]oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Exp Opin Orphan Drugs 2014; 2:87-94.
68. ClinicalTrials.gov. Pharmacokinetic and safety trial to determine the appropriate dose for pediatric patients with multidrug resistant tuberculosis. http://clinicaltrials.gov/ct2/show/NCT01856634?term=delamanid&rank=4. [Accessed 15 January 2014].
69. Stop TB Partnership Working Group on New TB Drugs. Drug pipeline. www.newtbdrugs.org/. [Accessed 25 January 2014]
70. Gopal M, Padayatchi N, Metcalfe JZ, O'Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17:1001-1007.
71. Dawson R, Diacon A. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs 2013; 22:927-932.
72. Zimri K, Hesseling AC, Godfrey-Faussett P, et al. Why do child contacts of multidrug-resistant tuberculosis not come to the assessment clinic? Public Health Action 2012; 2:71-75.
73. Seddon JA, Hesseling AC, Dunbar R, et al. Decentralised care for child contacts of multidrug-resistant tuberculosis. Public Health Action 2012; 2:66-70.
74. Treatment Action Group, Sentinel Project. We can heal-prevention, diagnosis, treatment, care, and support: addressing drug-resistant tuberculosis in children. http://www.treatmentactiongroup.org/tb/publications/2013/we-can- heal. [Accessed 25 January 2014]
75. Isaakidis P, Paryani R, Khan S, et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India. PLoS One 2013; 8:e68869.
76. Rose PC, Schaaf HS, du Preez K, et al. Completeness and accuracy of paediatric electronic drug-resistant tuberculosis registration in Cape Town, South Africa. Public Health Action 2013; 3:214-219.